Ireland procures Sobi therapies for all haemophilia patients
admin 7th February 2018 Uncategorised 0The Republic of Ireland has become the first country in Europe to switch its entire population with haemophilia A and B treated with short-acting replacement clotting factors to Swedish Orphan Biovitrum’s (Sobi) extended half-life therapies Elocta and Alprolix.
More: Ireland procures Sobi therapies for all haemophilia patients
Source: News